title: Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material.
abstract: Paraffin-embedded surgical specimens from 136 primary human central nervous system (CNS) tumors, including 50 meningiomas, 24 astrocytomas, 26 anaplastic astrocytomas, 9 glioblastomas, 8 oligodendrogliomas, 4 ependymomas, 1 anaplastic ependymoma, 2 subependymomas, 9 medulloblastomas, and 3 paragangliomas, were immunostained, following microwave processing, using a streptavidin/peroxidase method and the MIB 1 monoclonal antibody (mAb) against the Ki-67 antigen. The following mean Ki-67 labeling index (LI) values +/- SD were found: meningiomas, 2.47 +/- 1.83; astrocytomas, 2.03 +/- 2.03; anaplastic astrocytomas, 12.80 +/- 6.29; glioblastomas, 14.57 +/- 6.77; oligodendrogliomas, 5.06 +/- 4.78; ependymomas, 2.63 +/- 2.58; anaplastic ependymoma, 6.89; subependymomas, 1.79 +/- 1.54; medulloblastomas, 18.77 +/- 9.65; and paragangliomas, 2.19 +/- 2.51. Our findings indicate that while malignant CNS tumors always exhibited high Ki-67 LI values, and benign CNS tumors generally displayed lower values, increased immunoreactivity for Ki-67 epitopes (Ki-67 LI higher than 4) was noted in a number of meningiomas, astrocytomas, ependymomas, oligodendrogliomas and paragangliomas, contrasting with their benign histological features. Further investigations of the Ki-67 immunoreactivity in CNS tumors and systematic correlation with the postoperative follow-up of patients are necessary to determine the value of Ki-67 LI in predicting the biological behavior of CNS neoplasms.
authors.affiliation: Sandoz Pharma Ltd., Department of Toxicology, Basle, Switzerland.
authors.forename: E
authors.initials: E
authors.lastname: Karamitopoulou
authors.forename: E
authors.initials: E
authors.lastname: Perentes
authors.forename: I
authors.initials: I
authors.lastname: Diamantis
authors.forename: T
authors.initials: T
authors.lastname: Maraziotis
mesh_terms: D000911:Antibodies, Monoclonal; D001254:Astrocytoma / Q000473:pathology; D001932:Brain Neoplasms / Q000473:pathology; D016543:Central Nervous System Neoplasms / Q000473:pathology*; D004806:Ependymoma / Q000473:pathology; D000939:Epitopes / Q000032:analysis; D005909:Glioblastoma / Q000473:pathology; D006801:Humans; D007124:Immunoenzyme Techniques; D019394:Ki-67 Antigen; D008577:Meningeal Neoplasms / Q000473:pathology; D008579:Meningioma / Q000473:pathology; D009363:Neoplasm Proteins / Q000032:analysis*; D009687:Nuclear Proteins / Q000032:analysis*; D009837:Oligodendroglioma / Q000473:pathology; D010235:Paraganglioma / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D000939:Epitopes; D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D009687:Nuclear Proteins